SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: BigKNY3 who wrote (7028)2/17/1999 2:10:00 PM
From: Anthony Wong  Respond to of 9523
 
Lipitor Approved In Canada For Three New Indications
February 17, 1999

TORONTO, ON. -- Health Canada has approved three new indications for
Parke-Davis' and Pfizer Canada Inc.'s cholesterol-lowering drug Lipitor(R)(atorvastatin
calcium) to include use as an adjunct to diet for the following conditions:
dysbetalipoproteinemia (Type III); hypertriglyceridemia (Type IV); and homozygous
familial hypercholesterolemia (as an adjunct to LDL apheresis if available, otherwise as
monotherapy).

Lipitor is also indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B
and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia.

The recommended starting dose of Lipitor is 10mg once daily. The dosage range is 10 to
80 mg once daily.

Lipitor has been shown in clinical studies to produce reductions in LDL-cholesterol in
patients with elevated cholesterol of 39 percent to 60 percent across the dose range of
10 to 80 mg. Reductions in triglycerides of 19 percent to 37 percent were reported in
clinical trials in patients with mild to moderate hypercholesterolemia across the same
dose range. Furthermore, in clinical trials with Lipitor (10 to 80 mg) in patients with
hypertriglyceridemia show further reductions of triglycerides by 25 to 56 percent.

Lipitor is generally well tolerated. Adverse reactions are similar to other statins and have
usually been mild and transient, with fewer than two percent of patients being
discontinued from clinical trials due to side effects related to Lipitor. This rate of
discontinuation was comparable to that of placebo. The most frequent adverse events of
atorvastatin reported during clinical trials are constipation, flatulence and dyspepsia. It is
recommended that liver functions tests be performed prior to initiating therapy and
periodically thereafter. Myopathy should be considered in any patient with diffuse
myalgias, muscle tenderness or weakness, and/or marked elevation of creatine
phosphokinase, which may be more frequent when co-administered with drugs that
inhibit the cytochrome P-450 metabolising enzyme system.

pslgroup.com



To: BigKNY3 who wrote (7028)2/17/1999 3:52:00 PM
From: Anthony Wong  Respond to of 9523
 
Money Manager Picks Internet, Drug Stocks: Bloomberg Forum

Bloomberg News
February 17, 1999, 2:52 p.m. ET

Money Manager Picks Internet, Drug Stocks: Bloomberg Forum

Boca Raton, Florida, Feb. 17 (Bloomberg) -- Technology
stocks are likely to continue to lead the market as the growth of
the Internet drives big gains in revenue, a Boca Raton, Florida,
money manager said.

The rapid growth of the Internet, increasing spending by
U.S. baby boomers, and the aging of the U.S. population are three
long-term themes expected to benefit selected companies, said
William Welch, president of Oaktree Asset Management Inc. in Boca
Raton.

Even with many Internet stocks soaring in value over the
past year, technology stocks provide the most compelling
investment opportunities, said Welch, who manages about
$110 million in assets. He cited companies with strong niches
such as At Home Corp. and DoubleClick Inc.

''We think technology will be where most of your major
growth will be for the foreseeable future,'' Welch told the
Bloomberg Forum. ''There's a revolution in technology and
telecommunications, which is the strongest theme of all.''

At Home, based in Redwood City, California, provides
Internet services over high-speed cable-television lines, a
technology Welch sees as having potential for rapid growth. Last
month, the company agreed to acquire Excite Inc., the No. 2
Internet-search service.

''The slowness of data is a big problem,'' Welch said.
''Increasing broadband levels will be crucial. We think there's a
lot of growth potential.''

DoubleClick, an Internet advertising agency based in New
York, is expected to rise as more companies increase advertising
on the Internet, he said.

Another pick, Axent Technologies Inc., which provides
security systems for corporate computer networks, will gain from
the growing interest in protecting electronic information, Welch
said. Axent is based in Rockville, Maryland.

Baby Boomers

The bulge in the U.S. population following World War II has
boosted the earnings of companies that make and sell consumer
products from diapers and toys to videocassette recorders, said
Welch.

While it will be another decade before the first of the baby
boomers turns 65, the rising number of senior citizens is fueling
growth among drug manufacturers, he said.

''The aging of the baby boom crowd will be a driving force
in the economy,'' he said.

Welch likes Merck & Co., Eli Lilly and Co. and Pfizer Inc.
among larger companies, as well as Monsanto Co.
, whose Searle
line of pharmaceuticals includes oral contraceptives and
arthritis drugs. He also likes Sunrise Assisted Living Inc.,
which provides health and housing services for elderly people.

The manager is avoiding health-maintenance organizations and
hospital-management companies because they are subject to greater
government regulation.

With the first baby boomers now in their 50s, more are
taking time to travel. That makes stocks of Carnival Corp., the
world's largest cruise company, and Walt Disney Co. attractive,
Welch said.

Another area he likes is oil-services companies, whose
stocks have plunged with falling oil prices. A resumption in
growth in emerging markets of Asia will benefit companies led by
Schlumberger Ltd. and Halliburton Co., he said.

''The energy area probably provides the best overall value
for long-term portfolios,'' Welch said. ''It hasn't been a fun
place to be the last two years, but long-term you are going to
make money there.'' --Steve Matthews in Atlanta (404) 526-9553 through the Princeton



To: BigKNY3 who wrote (7028)2/17/1999 6:12:00 PM
From: Anthony Wong  Respond to of 9523
 
Prescriptions For Monsanto's Arthritis Drug Continue To Rise
February 17, 1999 2:16 PM

CHICAGO -(Dow Jones)- Monsanto Co.'s arthritis-pain drug Celebrex
continues to chalk up new prescriptions at a pace unprecedented for that
drug category.

In its fourth week on the market, the new medication produced 115,000
prescriptions, up from 83,000 during the third week. It thus continues to
rank No. 2 among recent drugs in racking up prodigious early sales.

Celebrex lags only Viagra, the impotence drug from Pfizer Inc. (PFE),
which achieved 294,000 prescriptions during its fourth week on the
market before peaking after three months.

Celebrex continues to significantly outpace the fourth-week sales of
cholesterol medication Lipitor, the No. 3 recent drug in generating early
sales. It entered the market in 1997. Lipitor, sold by Warner-Lambert Co.
(WLA), is projected to be a $3 billion drug this year. The prescription
figures were supplied by NDC Health Information Services, a leading
supplier of market data to the pharmaceutical industry.

Monsanto (MTC) co-markets Celebrex with Pfizer, and the two are
expected to share profits from the drug. The companies haven't disclosed
how profits are to be divided. However, some analysts estimate that
Monsanto will keep 55 to 60% of the profit. These rough estimates are
based on Wall Street's analysis of the experience with Lipitor, which is
also co-marketed with Pfizer.

The Celebrex numbers are especially impressive, given that Monsanto, of
St. Louis, and Pfizer, of New York, haven't really begun marketing yet.
The official beginning of marketing is next week. "Detailing" visits to
doctors, along with advertising supporting the drug, will start then.

Celebrex is the first of a new class of arthritis drugs known as Cox-2
inhibitors. They act against an enzyme, part of the pain process, that is
called cyclooxygenase-2, or Cox-2 for short. The Cox-2 drugs have
special promise, in the view of many doctors, because clinical data
suggest that these medications may not cause damage to patients'
gastrointestinal tracts, as current drugs do. The current pain drugs,
called NSAIDs for nonsteroidal anti-inflammatory drugs, lead to bleeding
ulcers in a small minority of patients. Bleeding ulcers sometimes are
fatal, and doctors have been looking for a gentler medication for chronic
treatment of pain.

- By Thomas M. Burton; 201-938-5099

Copyright (c) 1999 Dow Jones & Company, Inc.

All Rights Reserved.

smartmoney.com



To: BigKNY3 who wrote (7028)2/17/1999 9:09:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 9523
 
IMS HEALTH Reports More Than 110,000 Celebrex Prescriptions Dispensed in Second Week of February, Mail Order Prescriptions Gain Momentum

Wednesday February 17, 4:44 pm Eastern Time

Company Press Release

LONDON--(BW HealthWire)--Feb. 17, 1999-- IMS HEALTH (NYSE:RX - news) today reported that for the week ending Feb. 12, total prescriptions dispensed for Celebrex in the U.S. are estimated to break the 110,000 mark - up from 93,838 total prescriptions dispensed the previous week. Celebrex is the first in a new class of drugs called Cox-2 inhibitors, used to treat the symptoms of rheumatoid arthritis as well as osteoarthritis. IMS HEALTH's regular weekly prescription activity report covering the week ending Feb. 12 becomes available Monday, Feb. 22. IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries.

According to IMS HEALTH, fast uptake within the mail order channel is evident as Celebrex dispensed total prescriptions jumped from 382 for the week ending Jan. 29 to 2,608 for the week ending Feb. 5. The mail order prescription size average is 124 Celebrex tablets per prescription.

Primary Care Physicians, who wrote 48.9 percent of Celebrex prescriptions dispensed in the week ending Feb. 5, represent the majority of physicians prescribing Celebrex. In a slight shift from the previous week, Orthopedic Surgeons prescribed 16.5 percent of the dispensed Celebrex prescriptions, up from 15 percent the week ending Jan. 29. Rheumatologists, which last week was the number two category of prescribers with 20.4 percent of the total, now represents 15.3 percent of Celebrex prescriptions written.

IMS HEALTH's weekly prescription tracking service provides comprehensive coverage of three U.S. retail channels -- chain drug stores, independent pharmacies and food stores with pharmacies -- and includes cash and Medicaid prescriptions as well as third-party reimbursement. The service also provides unique access to mail-order prescriptions, making it the most complete market tracking service covering the U.S. pharmaceutical industry.

IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries. With more than $1 billion in 1997 revenue, IMS HEALTH operates in over 90 countries. IMS HEALTH is the largest pharmaceutical manufacturer information partner, with over 40 years' experience in the industry. Key products and services integral to customer day-to-day operations include: market research for prescription and over-the-counter pharmaceutical products; sales management information to optimize sales force productivity; technology enabled selling solutions for sales and marketing decision-making; and technology systems and information services that support managed care organizations. Additional information and previous press releases are available at IMS HEALTH's web site: imshealth.com.

Contact:

IMS HEALTH
Nancy Duckwitz
610/834-5338
or
Michael Gury
203/222-4230 (U.S.)
44-171-393-5864 (U.K.)

biz.yahoo.com